Our Work

In the News

Jack Henningfield and Sid Schnoll Submitted Comments on FDA Category 4 Labeling

View Henningfield PDF»

View Schnoll PDF»

Michael Hufford Presented New Research Showing Mobile Health Apps Could Support Novel OTC Switches

View PDF»

Pink Sheet interviewed Michael Hufford about nonprofit Harm Reduction Therapeutics’ goal of low-cost OTC naloxone

Pink Sheet»

Pinney Associates’ Scientific Abuse Potential Assessment of Kratom Finds Evidence of Public Health Benefit and Little Harm

View Press Release»

View 8-Factor Analysis»

More Smokers Trying to Quit – PinneyAssociates’ Analysis of National Health Interview Survey Data Confirms Increase in Attempts to Quit Smoking

View PDF»

PinneyAssociates Presents at FDA Public Meeting to Help Facilitate the Development of Abuse Deterrent Opioids

Learn what Ed Cone said about the FDA Abuse-Deterrent Guidance for Innovator and Generic Opioids

Watch Video »

PinneyAssociates Offers ALERRT® Methodology for In Vitro Assessment of Abuse-Deterrent Formulations

View PDF »

otc-icon

Can consumers self-select for appropriate use of an over-the-counter statin? The Self Evaluation of Lovastatin to Enhance Cholesterol Treatment Study

Brass EP, Vassil T, Replogle A, Hwang P, Rusche S, Shiffman S, Levine JG

Consumer understanding of prescription drug information: An illustration using an antidepressant medication.

Shiffman S, Gerlach KK, Sembower M, Rohay JM

Consumers appropriately self-treat based on labeling for over-the-counter hydrocortisone

Ellis CN, Pillitteri J, Kyle TK, Ertischek MD, Burton SL, Shiffman S

Ten years after the Rx-to-OTC switch of nicotine replacement therapy: what have we learned about the benefits and risks of non-prescription availability?

Shiffman S, Sweeney CT

perscription-icon

The ALERRT® instrument: a quantitative measure of the effort required to compromise prescription opioid abuse-deterrent tablets.

Cone EJ, Buchhalter AR, Lindhardt K, Elhauge T, Dayno JM

Abuse potential assessment of novel opioid analgesic NKTR-181: implications for labeling and scheduling

Webster LR, Smith S, Silowsky J, Gogas K, Odinecs A, Eldon M, Abrouk N, Medve R, Henningfield JE, Buchhalter AR, Cone EJ, Fant RV, Schnoll S

An iterative model for in vitro laboratory assessment of tamper deterrent formulations

Cone EJ, Giordano J, Weingarten B

Do prescription monitoring programs impact state trends in opioid abuse/misuse?

Reifler LM, Droz D, Bailey JE, Schnoll S, Fant RV, Dart RC, Bucher Bartelson B

Epidemiology of stimulant misuse and abuse: implications for future epidemiologic and neuropharmacologic research

Gerlach KK, Dasgupta N, Schnoll S, Henningfield JE

Establishing “abuse-deterrence equivalence” for generic abuse-deterrent opioid formulations: A proposed development framework

Setnik B, Cone EJ

Extreme work requirement of EG-001, an abuse-deterrent, extended-release morphine product, as demonstrated with the ALERRT® Visual Analog Scales.

Cone EJ, Buchhalter AR, Lindhardt K, Elhauge T, Dayno JM

Nonmedical use of prescription ADHD stimulants and preexisting patterns of drug abuse

Sweeney CT, Sembower M, Ertischek MD, Shiffman S, Schnoll S

The new science of abuse-deterrence assessment of pharmaceutical products; FDA proposed guidance and Category 1 laboratory studies

Cone EJ, Buchhalter AR, Henningfield JE, Schnoll S

Events

August 9-12 | San Francisco, CA

Who will be there: Jack Henningfield, Annie Kleykamp

Tobacco Product Abuse Liability Assessment—Challenges for FDA and Behavioral Science

October 1 | Washington, DC

Who will be there: Jack Henningfield

Topic: The Future of Pain Control

November 15 | London, UK

Who will be there: Saul Shiffman, Robyn Gougelet

November 14-16 | Palm Springs, CA

Who will be there: Joe Gitchell